Hisamitsu Transdermal OAB Drug Shows Promising Results In Phase III
Japan's first transdermal formulation of oxybutynin, a treatment for overactive bladder has shown promising results in a confirmatory Phase III trial, Hisamitsu Pharmaceutical said
Japan's first transdermal formulation of oxybutynin, a treatment for overactive bladder has shown promising results in a confirmatory Phase III trial, Hisamitsu Pharmaceutical said